Medicare prescriptions for Wegovy jumped after approval for heart disease
Medicare prescriptions for the weight-loss drug Wegovy increased significantly after the FDA approved it for heart disease risk reduction. Despite this, researchers note that only a small fraction of eligible beneficiaries are currently receiving the treatment.
Why it matters
The findings highlight the gap between drug approval and actual patient access within public health programs, as well as the ongoing debate over covering expensive GLP-1 medications.
edited by Sadie Harley , reviewed by Andrew Zinin
The article relies on research data and explains policy changes without ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in